FENNEC PHARMACEUTICALS INC. Cost of Revenue
FENNEC PHARMACEUTICALS INC. (FENC) reported Cost of Revenue of $1.26 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2024-03-29
- FENNEC PHARMACEUTICALS INC. cost of goods and services sold for the quarter ending 2023-12-31 was $685.00K.
- FENNEC PHARMACEUTICALS INC. cost of goods and services sold for the quarter ending 2023-09-30 was $331.00K.
- FENNEC PHARMACEUTICALS INC. cost of goods and services sold for the quarter ending 2023-06-30 was $148.00K.
- FENNEC PHARMACEUTICALS INC. cost of goods and services sold for the quarter ending 2023-03-31 was $95.00K.
- FENNEC PHARMACEUTICALS INC. cost of goods and services sold for fiscal 2023 was $1.26M, a 1363.95% increase from fiscal 2022.
- FENNEC PHARMACEUTICALS INC. cost of goods and services sold for fiscal 2022 was $86.00K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2023-12-31 | $685.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.02M derived: sum of 2 quarters · filed 2024-03-29 | $1.16M derived: sum of 3 quarters · filed 2024-03-29 | $1.26M 10-K · filed 2024-03-29 |
| 2023-09-30 | $331.00K 10-Q · filed 2023-11-09 | $479.00K derived: sum of 2 quarters · filed 2023-11-09 | $574.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $148.00K 10-Q · filed 2023-08-07 | $243.00K 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | $95.00K 10-Q · filed 2023-05-12 | |||
| 2022-12-31 | $86.00K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |